{"organizations": [], "uuid": "bdfc89cf5f0c95e21a4075d234f5d59a2fa1a895", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-eisai-co-merck-announce-oncology-c/brief-eisai-co-merck-announce-oncology-collaboration-for-lenvima-idUSFWN1QP0XU", "country": "US", "domain_rank": 408, "title": "BRIEF-Eisai Co, Merck Announce Oncology Collaboration For Lenvima", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-08T00:37:00.000+02:00", "replies_count": 0, "uuid": "bdfc89cf5f0c95e21a4075d234f5d59a2fa1a895"}, "author": "", "url": "https://www.reuters.com/article/brief-eisai-co-merck-announce-oncology-c/brief-eisai-co-merck-announce-oncology-collaboration-for-lenvima-idUSFWN1QP0XU", "ord_in_thread": 0, "title": "BRIEF-Eisai Co, Merck Announce Oncology Collaboration For Lenvima", "locations": [], "entities": {"persons": [{"name": "merck", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-eisai co", "sentiment": "negative"}, {"name": "merck announce oncology collaborat", "sentiment": "negative"}, {"name": "merck announce oncology collaboration", "sentiment": "negative"}, {"name": "lenvima reuters", "sentiment": "none"}, {"name": "eisai", "sentiment": "none"}, {"name": "merck & co inc", "sentiment": "none"}, {"name": "merck & co - co", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "keytruda", "sentiment": "none"}, {"name": "eisai co ltd", "sentiment": "none"}, {"name": "merck", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 7, 2018 / 10:40 PM / Updated 11 minutes ago BRIEF-Eisai Co, Merck Announce Oncology Collaboration For Lenvima Reuters Staff March 7 (Reuters) - Eisai Co Ltd: * EISAI CO., LTD. AND MERCK ENTER GLOBAL STRATEGIC ONCOLOGY COLLABORATION FOR LENVIMA® (LENVATINIB MESYLATE) * MERCK & CO - CO, ‍​ISAI TO DEVELOP AND COMMERCIALIZE LENVIMA JOINTLY, BOTH AS MONOTHERAPY AND IN COMBINATION WITH MERCK’S ANTI-PD-1 THERAPY, KEYTRUDA * MERCK & CO INC - GROSS PROFITS FROM LENVIMA PRODUCT SALES GLOBALLY WILL BE SHARED EQUALLY BY EISAI AND MERCK * MERCK & CO - EXPENSES INCURRED DURING CO-DEVELOPMENT, INCLUDING FOR STUDIES EVALUATING LENVIMA AS MONOTHERAPY, TO BE SHARED EQUALLY BY CO, EISAI * MERCK - TO PAY EISAI UPFRONT PAYMENT OF $300 MILLION U.S. DOLLARS AND UP TO $650 MILLION U.S. DOLLARS FOR CERTAIN OPTION RIGHTS THROUGH 2020 AS PER DEAL * MERCK - TO ALSO PAY EISAI $450 MILLION AS REIMBURSEMENT FOR RESEARCH AND DEVELOPMENT EXPENSES AS PER DEAL * MERCK & CO INC - EISAI IS ELIGIBLE TO RECEIVE MAXIMUM OF UP TO $3.97 BILLION FOR ACHIEVEMENT OF MILESTONES ASSOCIATED WITH SALES OF LENVIMA * MERCK - AS PER DEAL, ‍EISAI IS ELIGIBLE TO RECEIVE UP TO $385 MILLION ASSOCIATED WITH ACHIEVEMENT OF CERTAIN CLINICAL AND REGULATORY MILESTONES​ * MERCK & CO - ASSUMING ACHIEVEMENT OF ALL GOALS FOR ALL INDICATIONS AS PER DEAL, TOTAL AMOUNT OF PAYMENTS TO EISAI COULD REACH UP TO $5.76 BILLION Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-08T00:37:00.000+02:00", "crawled": "2018-03-08T00:54:43.000+02:00", "highlightTitle": ""}